Understanding how individual responses to treatments vary in ARDS and sepsis
Official title: Improving Characterization of Individualized Treatment Effects in Critical Illness
Funded at University of Pittsburgh at Pittsburgh · NIH-11403905 · Data updated 2026-11-12
This grant aims to help clinicians predict which patients with ARDS or sepsis will benefit most from specific treatments by using advanced computer approaches.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project start | September 1, 2025 |
| Project end | August 31, 2030 |
| Funding year | 2026 |
| Award (this year) | $437,250 |
| NIH project number | 5R35GM160146-02 |
| Project ID | NIH-11403905 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with ARDS or sepsis who could be candidates for standard therapies in the ICU.
✕Less likely to help
Patients not eligible for the studied therapies or with conditions excluding ICU treatment would not benefit.
What this research studies
Patients with ARDS or sepsis often respond very differently to the same therapy. The project uses machine learning methods to estimate individualized treatment effects, helping doctors tailor therapies to each person. It builds on previous work identifying subgroups and adds tools to quantify how much a given patient is likely to benefit or be harmed by a treatment. The research focuses on making these personalized estimates reliable enough for use in critical care decisions.
Why it matters
Potential benefit: If successful, clinicians could personalize treatments for ARDS/sepsis, potentially improving outcomes and reducing harm.
How similar studies have gone: Previous work has shown subphenotypes; this project extends to individualized treatment effects and deeper patient-specific predictions.
Where this research is happening
-
University of Pittsburgh at Pittsburgh
Pittsburgh, United States Active
Researchers
- Principal investigator: Shah, Faraaz Ali — University of Pittsburgh at Pittsburgh
- Study coordinator: Shah, Faraaz Ali
Related research
Other NIH-funded projects on the same topics.
-
Glucocorticoids and critical illness outcomes in ICU patients
A researcher team at Columbia University will study how glucocorticoids affect short- and long-term outcomes for people who survive critical illness, including mental health and recovery aspects.
-
REPAIR-ICU: Understanding aging-like changes after critical illness to help ICU survivors
This grant studies how surviving an ICU stay triggers aging-related changes in the body and tests interventions to help people recover.
-
Myeloid-Derived Suppressor Cells in Immunological Endotyping and Intervention for Chronic Critical Illness after Sepsis
Aimed at people who have survived sepsis after surgery, this grant seeks to understand why some patients develop long-term organ problems and how to tailor treatments to their immune responses.
-
Molecular rules of capillary leak in seriously ill kids
A study looking at why blood vessels become leaky in severely ill children and how that leads to organ failure.
-
Heme-Driven Immune Dysregulation in Critical Illness
Researchers are studying how free heme from red blood cell breakdown affects the immune system in people with sepsis or chronic blood disorders, with the aim of guiding better treatments.
-
Remotely Monitored HIIT After COVID-19 ICU Stay
A home-based, high-intensity interval training program guided by wearable tech to help adults recover physical function after severe COVID-19 illness.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.